Psoriasis ungueal: tratamiento con ungüento hidrófilo de tazaroteno al 0.1 por ciento / Nail Psoriasis: Treatment With Tazarotene 0.1 percent Hydrophilic Ointment
Actas dermo-sifiliogr. (Ed. impr.)
; 103(8): 725-728, oct. 2012. ilus, tab
Article
in Spanish
| IBECS
| ID: ibc-108515
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
Introducción:
La afectación ungueal de la psoriasis es una presentación frecuente que interfiere de manera significativa en la calidad de vida de los pacientes. Su presentación clínica va a depender del área ungueal afecta lecho o matriz. Un 50% de los pacientes refiere dolor asociado. En este estudio evaluamos la eficacia y seguridad del tazaroteno 0,1% en ungüento hidrófilo. Material ymétodos:
Estudio abierto y observacional de 6 pacientes diagnosticados de psoriasis ungueal. Se aplicó ungüento de tazaroteno 0,1% (fórmula magistral) en oclusión nocturna, en su domicilio durante 6 meses, sin otro tratamiento tópico o sistémico. Se determinó el Nail Psoriasis Severity Index (NAPSI) y se evaluaron la hiperqueratosis subungueal, onicólisis, hemorragias en astilla, manchas de aceite y piquiteado ungueal, en la visita basal, a los 3 y 6 meses.Resultados:
Se observó una mejoría estadísticamente significativa en todos los pacientes NAPSI basal, media ± DE 14,3± 6,3; IC 95% 11,74-16,92; mediana 15; NAPSI a los 6 meses media ± DE 2,3 ±1,21; IC 95% 1,84-2,83; mediana 2,5; p=0,007. El porcentaje de mejoría fue del 87,9% al final del tratamiento. No se registraron efectos adversos.Conclusión:
Nuestro estudio muestra un potencial terapéutico del ungüento de tazaroteno en la psoriasis ungueal (AU)ABSTRACT
Introduction:
Nail involvement is common in psoriasis and has a considerable impact on patient quality of life. Its clinical presentation depends on which part of the nail is affected the bed or the matrix. Fifty percent of patients report associated pain. In this study, we analyzed the safety and effectiveness of tazarotene 0.1% in a hydrophilic ointment in the treatment of nail psoriasis. Material andmethods:
We performed an open observational study of 6 patients diagnosed with nail psoriasis. The patients applied a compounded preparation of tazarotene 0.1% ointment under occlusion every night for 6 months in their homes. They were not receiving any other topical or systemic treatments. Nail psoriasis severity (assessed using the Nail Psoriasis Severity Index [NAPSI]), subungual hyperkeratosis, onycholysis, splinter hemorrhages, oil stains, and nail pitting were evaluated at baseline and at 3 and 6 months.Results:
A statistically significant improvement between baseline and 6 months was observed in all patients the mean (SD) NAPSI went from 14.3 (6.3; 95% CI, 11.74-16.92) to 2.3 (1.21; 95% CI, 1.84-2.3) while the median went from 15 to 2.5 (P = 0.007). The percentage improvement at the end of treatment was 87.9%. No adverse effects were observed.Conclusion:
Our study shows the therapeutic potential of tazarotene ointment in nail psoriasis (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Ointments
/
Psoriasis
/
Treatment Outcome
/
Antifungal Agents
/
Nail Diseases
Type of study:
Observational study
Aspects:
Patient-preference
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Actas dermo-sifiliogr. (Ed. impr.)
Year:
2012
Document type:
Article
Institution/Affiliation country:
Hospital Universitari Sagrat Cor/España
/
Universidad de Barcelona/España